Agilent Technologiesvs.Danaher
A vs DHR · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 3.5× larger than Agilent Technologies by market cap; Agilent Technologies trades at the lower P/E (29.4 vs 35.9); year to date, Agilent Technologies leads (+12.8% vs −6.0%).
Side by side
| A | DHR | |
|---|---|---|
| Market cap | $41.5B | $144B |
| Price | $154.77 | $215.97 |
| Today | +0.9% | +0.4% |
| Return YTD | +12.8% | −6.0% |
| Return 1Y | +26.1% | +1.6% |
| P/E | 29.4 | 35.9 |
| P/S | 5.7 | 5.7 |
| P/B | 5.8 | 2.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Agilent TechnologiesA
Laboratory analysis is the business: LC/MS and other analytical instruments, sold with the consumables and diagnostic reagents that keep them running.
Full A profile →DanaherDHR
Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.
Full DHR profile →More A & DHR comparisons
Other head-to-heads in the Life science tools segment.